In addition to anti-inflammatory properties, baricitinib is a JAK inhibitor with potential antiviral effects, inhibiting AP2-associated kinase 1 (AAK1) and cyclin G-associated kinase (GAK) involved in SARS-CoV-2 endocytosis, i.e. viral infection of host cells (Jorgensen et al., 2020; Richardson et al., 2020; Spinelli et al., 2020). Here, AAK1 is linked to viral infectious disease.